Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

61.55 -0.06 (-0.10%)

Official Closing Price Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters ↗

Today 2:33 EDT

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Via The Motley Fool

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation ↗

October 26, 2026

Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.

Via The Motley Fool

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock ↗

October 26, 2026

Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.

Via MarketBeat

Topics Intellectual Property

Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors ↗

October 26, 2026

Via Chartmill

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

October 12, 2026

Via Chartmill

Bristol Myers Squibb: Bargain Buy or Value Trap? ↗

October 26, 2026

The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.

Via The Motley Fool

Topics Intellectual Property

3 High-Yield Stocks to Buy With $1,000 Right Now ↗

October 26, 2026

These stocks pay yields far above the S&P 500's. And they keep raising their dividends.

Via The Motley Fool

Topics Intellectual Property Stocks

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗

October 25, 2026

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Via The Motley Fool

Topics Intellectual Property

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? ↗

October 23, 2026

One of these pharma stocks offers more income, but the other offers a safer dividend.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue ↗

October 22, 2026

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Via The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility ↗

October 22, 2026

Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.

Via The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗

October 22, 2026

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Via The Motley Fool

Topics Artificial Intelligence Lawsuit

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗

October 21, 2026

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Via The Motley Fool

Topics Intellectual Property

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Via The Motley Fool

S&P 500 Top Movers: Gainers and Losers From Today's US Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait. ↗

October 20, 2026

Consider this pharma company's turnaround, not its dividend, its main appeal.

Via The Motley Fool

Topics Intellectual Property

October 20, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗

October 18, 2026

It has been a volatile year for the biotech.

Via The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 16, 2026

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

Via The Motley Fool

Topics Intellectual Property

These S&P500 stocks are gapping in today's session ↗

October 15, 2026

Via Chartmill

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks

October 13, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 13, 2026

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

Via The Motley Fool

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗

October 10, 2026

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 10, 2026

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Via The Motley Fool

2 Profitable Stocks to Target This Week and 1 We Find Risky

October 09, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 08, 2026

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) ↗

October 07, 2026

If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today.

Via The Motley Fool

Topics Bonds Intellectual Property

Uncover the latest developments among S&P500 stocks in today's session. ↗

October 05, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.